AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04529395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blending of essential oils
Description: The mixture of essential oils will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
Study NCT04529395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apricot vegetable oil
Description: The apricot vegetable oil will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
Study NCT00006371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aminoglutethimide
Study NCT00006371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole
Study NCT00006371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone
Study NCT02506231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Study NCT02506231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01987726 — intervention group
Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H\&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.
Study NCT01987726 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: 2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
Study NCT04712084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive pressure
Description: Inspiratory support of 8 cmH2O was applied associated with PEEP at 6 cmH2O. After extubation, same support was applied by facemask for 3 minutes
Study NCT02192294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Bosutinib
Description: a single dose of 500 mg oral bosutinib
Study NCT02192294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of bosutinib
Description: a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
Study NCT00515034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/cilastatin
Description: Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
Study NCT00515034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: 1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
Study NCT00515034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: 1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
Study NCT02130778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline
Description: infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
Study NCT02130778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 500 ml 0.9% saline
Description: infusion of saline
Study NCT02425384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (motivational website, activity meter)
Description: The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
Study NCT02425384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control (active video game, activity meter)
Description: The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
Study NCT02425384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive Control (activity meter)
Description: Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
Study NCT03992339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
Description: Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
Study NCT00521482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Study NCT04428580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online FBT Training
Description: Therapists will receive online training in Family-Based Treatment (FBT)
Study NCT04428580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Webinar FBT Training
Description: Therapists will receive webinar training in Family-Based Treatment (FBT)
Study NCT02974478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice between meals
Description: orange juice (20% of energy requirement/day)
Study NCT03204812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03204812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT03683433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT03683433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib Mesylate
Description: Given PO
Study NCT04430738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.
Study NCT02974478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar sweetened beverage between meals
Description: Sugar sweetened beverage (20% of energy requirement/day)
Study NCT04430738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Cohorts 1A and 1B: a 6 mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 Day 1, followed by a dose of 4 mg/kg IV every 2 weeks starting on Cycle 2 Day 1. Cohorts 1C, 1D, 1E, 1F, 1G, 2A, and 2B: an 8 mg/kg loading dose will be administered IV on Cycle 1 Day 1, followed by a dose of 6 mg/kg IV every 3 weeks thereafter.
Study NCT04430738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m\^2 given IV every 2 weeks for cohorts using FOLFOX. For cohorts using CAPOX regimen, 130 mg/m\^2 given every 3 weeks.
Study NCT04430738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 200 (mFOLFOX7) or 400 (mFOLFOX6) mg/m\^2 given IV every 2 weeks. Part of FOLFOX regimen.
Study NCT04430738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 400 mg/m\^2 (IV bolus after leucovorin) and/or 2400 mg/m\^2 (continuous infusion over 46 hours). Part of FOLFOX regimen.
Study NCT04430738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m\^2 is taken twice per day orally on Days 1-14 of each 3 week cycle. Part of CAPOX regimen.
Study NCT04430738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 400 mg given by IV on day 1 of cycle 1, then every 6 weeks.
Study NCT04149379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: 20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
Study NCT03217357 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial stimulation in direct current
Description: tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
Study NCT03217357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial stimulation in direct current
Description: tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
Study NCT04213729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Counseling
Description: Standard of care diet counseling provided at clinic visit 1.
Study NCT04261985 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: healthy weight behaviors supported by web-based mobile phone application
Description: Chorus is a mobile phone platform that provides texting, a web application, and an online community for mHealth interventions.Content is created using existing templates to insert text, images, pictures, audio, video clips, or any combination of these. Users interface with Chorus by clicking a hyperlink embedded in a text message sent to their phone to then access web-based interactions via prompts and clicks. Content was created in English and Spanish.
Study NCT00582296 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires, telephone interview, optional blood drawn
Description: Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
Study NCT00582296 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires, telephone interview and optional blood drawn
Description: Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family \& personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
Study NCT05535569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab, Paclitaxel
Description: Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.
Study NCT03926130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV
Study NCT03926130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study NCT04213729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD LFD
Description: Daily breakfast, lunch, dinner and snacks LFD catered meals. Meals will have approximately 20% calories from fat, a goal ratio close to 1:1 omega-6/omega-3 fatty acids, and approximately 25-35 grams of fiber per day.
Study NCT03926130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Administered IV
Study NCT03926130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Administered SC
Study NCT03926130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT03926130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04213729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Psychological Support (DPS)
Description: The dyadic psychosocial support (DPS) intervention will be provided for a total of 12 weeks. The 12-week DPS intervention consists of eight sessions (main sessions) and two booster sessions. The intervention will incorporate psychoeducational components that combine didactic and behavioral regulatory procedures to promote healthy diet behavior for self-determined reasons.
Study NCT03653338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3/CD19 depleted leukocytes
Description: Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.
Study NCT03653338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD45RA depleted leukocytes
Description: Negative selection for CD45RA will be performed on the CliniMACS® depletion device.
Study NCT03653338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Sickle Cell Disease Conditioning
Study NCT03653338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Sickle Cell Disease Conditioning
Study NCT03653338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Sickle Cell Disease Conditioning
Study NCT03653338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Sickle Cell Disease Conditioning
Study NCT02208765 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stress Single Photon Emission Computed Tomography
Study NCT01230411 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: 250 cc of placebo administered IV
Study NCT01230411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800 mg ibuprofen in 250 cc saline administered IV
Study NCT02427932 — intervention group
Intervention type: DRUG
Intervention: Ampicillin
Description: Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
Study NCT02427932 — intervention group
Intervention type: DRUG
Intervention: Ampicillin and Gentamicin
Description: Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
Study NCT02427932 — intervention group
Intervention type: DRUG
Intervention: Gentamicin
Description: Prescribed to non-pregnant participants
Study NCT02330003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG FLU Vaccine Prefilled Syringe INJ.
Description: Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
Study NCT02330003 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Prefilled Syringe
Description: Fluarix Prefilled Syringe 0.5mL
Study NCT04863404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face mask with hybrid-hyrax
Description: Face mask with hybrid-hyrax
Study NCT04863404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face mask with conventional bonded RME
Description: Face mask with conventional bonded RME
Study NCT00404248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terameprocol
Description: terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
Study NCT00404248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
Study NCT01616147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Description: Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
Study NCT01616147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
Study NCT01405196 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PF-04236921
Description: subcutaneous injection; administered at day 1, weeks 8, 16.
Study NCT01405196 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PF-04236921
Description: subcutaneous injection; administered at day 1, weeks 8, 16
Study NCT02755350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.
Study NCT03331887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: E-max CAD endocrown
Description: endocrown used to restore endodontically treated teeth with E-max CAD endocrowns
Study NCT03331887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: E-max CAd crowns retained with fiber reinforced composite post
Description: fiber reinforced composite post need to restore endodontically treated tooth with E-max crown
Study NCT03653338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Sickle Cell Disease Conditioning
Study NCT02498132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, \& Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).
Study NCT02498132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitvie Based Therapy
Description: CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
Study NCT00521482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide plus Thalidomide
Study NCT04890509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: Bemcentinib capsules will be administered orally.
Study NCT04890509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SoC
Description: The SoC will be administered based on local guidelines.
Study NCT04890509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC
Description: The SoC will be administered based on local guidelines.
Study NCT03255395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided focused ultrasound
Description: Ten amputees wil recieve a magnetic resonance-guided focused ultrasound treatment aimed at ablating neuromas, which are believe to contribute to their phantom / residual limb pain
Study NCT03671226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Given questionnaire
Study NCT02498132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Individuals will be provided with one on one therapy sessions
Study NCT01854242 — intervention group
Intervention type: OTHER
Intervention: Glycogen Storage Disease type Ia patients
Description: The participants will have one blood draw for this study. The test will be performed on the blood.
Study NCT00531973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)